News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apitope Led Consortium Receives Up To €6M FP7 Funding To Develop Novel Therapeutic Vaccine For Graves' Disease



1/8/2014 9:40:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISTOL, England & HASSELT, Belgium--(BUSINESS WIRE)--Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 (FP7) Health Innovation funding by the European Commission to develop its Graves’ disease therapeutic vaccine, including a Phase I first-in-man study in Graves’ disease patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Apitope
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES